Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Sboner A, Elemento O. A primer on precision medicine informatics. Brief Bioinform. 2016;17(1):145-53.

Poulos MG, Ramalingam P, Gutkin MC, Kleppe M, Ginsberg M, Crowley MJ, et al. Endothelial-specific inhibition of NF-κB enhances functional haematopoiesis. Nat Commun. 2016;7:13829.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;538(7625):397-401.

Masika LS, Zhao Z, Soldin SJ. Is measurement of TT3 by immunoassay reliable at low concentrations? A comparison of the Roche Cobas 6000 vs. LC-MSMS. Clin Biochem. 2016;49(12):846-9.

Reid MD, Basturk O, Shaib WL, Xue Y, Balci S, Choi H-, et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. Mod Pathol. 2016;29(10):1243-53.

Reich-Slotky R, Bachegowda LS, Ancharski M, Gergis U, Van Besien K, Cushing MM. Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion. 2016;56(4):893-8.

Li X, Tyler JK. Nucleosome disassembly during human non-homologous end joining followed by concerted HIRA- and CAF-1-dependent reassembly. Elife. 2016;5.

Sheikh UN, Cohen C, Siddiqui MT. Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Müllerian origin, and primary lung adenocarcinoma. Diagn Cytopathol. 2016;44(5):369-76.

Park HJ, Kim K, Paik JH, Chie EK, Kim S, Jang J-, et al. Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy? Clin Transl Oncol. 2016;18(6):625-31.

Mulvey JJ, Nuovo GJ, Magro CM. Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal. Am J Dermatopathol. 2016;38(7):492-8.